Literature DB >> 22261537

Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: results from an international survey and discussion programme.

Marc Ferrante1, Konstantinos Karmiris, Evan Newnham, Jesse Siffledeen, Zuzana Zelinkova, Gert van Assche, Peter L Lakatos, Julian Panés, Andreas Sturm, Simon Travis, C Janneke van der Woude, Walter Reinisch, Jean-Frédéric Colombel, Remo Panaccione.   

Abstract

BACKGROUND AND AIMS: Data on the optimal use of conventional therapies in Crohn's disease are lacking in guidelines. An educational programme was established to explore questions raised in clinical practice and to provide practical answers.
METHODS: Telephone interviews with 96 gastroenterologists and a web survey of 1370 gastroenterologists identified 26 key questions. Ten questions were taken forward to the next stage based on the opinion of an International Steering Committee. Draft answers to the questions were prepared from available evidence following a literature search. The draft answers were debated in national meetings of participating countries (n=36) and voted on using a standard scoring system. Revised answers went forward to an international meeting and were debated and voted on using the same methodology. Final answers were developed, based on evidence and clinical experience of the participants.
RESULTS: Evidence on corticosteroid and immunomodulator use such as dosage, timing and duration, choice of drug or regimen, and safety is scarce. Key points of the answers included the importance of: identifying patients with poor prognosis; early intervention with optimal doses of immunomodulators; avoiding prolonged or repetitive corticosteroid therapy; achieving corticosteroid-free remission; achieving a balance between clinical benefit and safety when intensifying or prolonging therapy or combining different agents; re-evaluating therapy at appropriate time points; and considering the role of biomarkers and mucosal healing.
CONCLUSIONS: The answers to 10 key questions were based on available evidence and clinical experience of programme participants. It is hoped they will be of practical use in everyday gastroenterology practice.
Copyright © 2011 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22261537     DOI: 10.1016/j.crohns.2011.09.009

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  3 in total

1.  Efficacy of Adalimumab in Korean Patients with Crohn's Disease.

Authors:  Il Woong Sohn; Sung Tae Kim; Bun Kim; Hyun Jung Lee; Soo Jung Park; Sung Pil Hong; Tae Il Kim; Won Ho Kim; Jae Hee Cheon
Journal:  Gut Liver       Date:  2016-03       Impact factor: 4.519

Review 2.  Expert opinion on the use of cladribine tablets in clinical practice.

Authors:  Per Soelberg Sørensen; Diego Centonze; Gavin Giovannoni; Xavier Montalban; Daniel Selchen; Patrick Vermersch; Heinz Wiendl; Bassem Yamout; Hashem Salloukh; Peter Rieckmann
Journal:  Ther Adv Neurol Disord       Date:  2020-06-24       Impact factor: 6.570

Review 3.  Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice.

Authors:  Peter Rieckmann; Diego Centonze; Gavin Giovannoni; Le H Hua; Celia Oreja-Guevara; Daniel Selchen; Per Soelberg Sørensen; Patrick Vermersch; Heinz Wiendl; Hashem Salloukh; Bassem Yamout
Journal:  Ther Adv Neurol Disord       Date:  2021-12-07       Impact factor: 6.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.